Over the past year AVI Biopharma's fortunes have been transformed. Its stock price has more than tripled as it has pushed new RNA programs for Duchenne Muscular Dystrophy and the Ebola and Marburg viruses. The developer moved from Portland to a new home in the Bothell, WA cluster. And it's raised $50 million from its fattened stock to help continue work that has so far consumed $271 million in R&D costs. "We were one of two healthcare-based companies in Corvallis, and now we're one of 200 in the Bothell area," CEO Les Hudson tells Xconomy. Report